There is a conversation happening in procurement offices across the country right now that would have sounded strange five years ago. It isn’t about price. It’s about whether the vendor will actually deliver.
For most of the last two decades, healthcare facility supply management followed a straightforward playbook. Negotiate the best contract through your GPO, lock in a primary vendor, reorder when stock runs low, and move on to the next problem. That model worked when the supply chain was predictable. It doesn’t work anymore.
The numbers tell the story. ASHP’s drug shortage statistics tracked 323 active drug shortages in early 2024, the highest count since tracking began in 2001. By early 2026, the number of active shortages hovered around 270. Alarmingly, 75% of these deficits date back to 2022 or earlier, signaling a shift from temporary crises to permanent systemic failures. The most severely impacted supplies—sterile injectables, IV fluids, and oncology medications—are far from optional. They are the absolute foundation of daily patient care across the nation’s infusion centers, surgical units, and acute care facilities.
Then came the tariffs. Chinese imports on medical devices climbed to 145 percent in 2025. Johnson & Johnson projected $400 million in tariff-related costs for its MedTech division alone. A Becker’s Hospital Review survey of supply chain leaders found that heading into 2026, the concerns have shifted from acute shortages to structural pressures: reimbursement declines, cost escalation, geopolitical instability, and the practical limits of automation. The margin for error, as one leader put it, is narrowing.
The Single-Vendor Problem
When Hurricane Helene hit North Carolina in late 2024, it did not just damage a building. It knocked out a Baxter International manufacturing plant that produced a significant share of the nation’s large-volume IV fluids. Within days, 84 percent of pharmacy teams nationwide reported moderate or critical impact, according to an ASHP sterile fluid shortage survey. Facilities in Florida and across the Southeast scrambled for alternatives. Surgery centers rescheduled procedures. Infusion centers rationed saline.
The facilities that recovered fastest weren’t the largest or the best funded. They were the ones that had already diversified their vendor relationships before the crisis arrived. They had secondary suppliers with active purchase histories, which meant they qualified for allocation when supply tightened. They had pre-approved therapeutic interchange protocols, so their clinical teams could pivot without weeks of committee deliberation. They treated medical supply procurement as a strategic function, not an administrative task.
What Rethinking Vendor Relationships Actually Looks Like
Diversification doesn’t mean spreading orders across ten vendors for the sake of it. It means identifying which product categories carry the highest disruption risk and ensuring that no single supplier controls your access to those products. For most facilities, that starts with sterile injectables, IV fluids, and controlled substances, the categories that appear most frequently on FDA’s drug shortage database and ASHP shortage lists.
From there, the shift is both practical and cultural. On the practical side, facilities need to maintain active purchasing volume with at least two qualified vendors per high-risk category. Allocation during a shortage is almost always tied to historical purchase data. If you have never ordered from a supplier before, your allocation is zero when the shortage hits, regardless of how urgently you need the product.
On the cultural side, procurement teams need a seat at the same table as clinical and financial leadership. GHX’s 2026 supply chain predictions describe this as supply chain becoming the enterprise orchestrator of risk and resilience. That’s not a department title. It’s a recognition that purchasing decisions now directly affect whether a patient receives treatment on time. Healthcare facility supply management can’t remain a back-office function when it determines clinical outcomes.
Compliance Adds Another Layer
The vendor relationship conversation doesn’t end with availability. DSCSA compliance deadlines are now active across the supply chain. Manufacturers hit their serialization requirements in May 2025. Wholesale distributors followed in August. Dispensers are on a rolling timeline through November 2026. Every vendor a facility purchases prescription products from must provide electronic, package-level traceability documentation. Noncompliance carries civil fines up to $500,000 per violation.
That means vendor vetting now includes a compliance dimension that didn’t exist three years ago. Facilities need to confirm not just that a supplier can deliver product, but that the supplier can deliver compliant product with full chain-of-custody documentation. Any vendor that can’t meet that standard is a liability, not a partner.
The Facilities That Prepare Will Lead
None of this is comfortable. Diversifying vendors takes time. Building secondary relationships requires purchase commitments. Getting procurement a seat at the leadership table means changing how organizations think about supply decisions. But the alternative is what we saw after Helene: cancelled procedures, rationed saline, and clinical teams spending their mornings on the phone instead of with patients.
The medical supply chain isn’t going back to the way it was. Tariff pressures, manufacturing concentration, regulatory complexity, and climate-driven disruptions are structural realities now. The facilities that acknowledge this and build their vendor strategies and procurement infrastructure accordingly won’t just survive the next disruption. They will be the ones still operating at full capacity while their neighbors scramble.
About the Author
This article was contributed by the team at USA MedPremium, a Florida-based medical supply company serving hospitals, medical practices, infusion centers, surgery centers, aesthetic clinics, home care agencies, and specialty pharmacies nationwide. With a catalog of over 500,000 products across 1000+ categories, USA MedPremium provides DSCSA-compliant, multi-manufacturer sourcing designed to help healthcare facilities maintain supply continuity through market disruptions.
You must be logged in to post a comment.